Why Is Progyny (PGNY) Stock Down -8.61% Today?
Key Takeaways
- Progyny shares tumbled 8.61% to $27.61 in Friday trading, following a sharp after-hours selloff triggered by the company's second-quarter earnings report released Thursday evening.
- Despite beating Q2 top- and bottom-line estimates, the company's Q3 revenue guidance of $335 million to $345 million came in well below Wall Street's consensus of approximately $350.6 million, rattling investor sentiment.
- Management attributed the softer forward outlook to a more pronounced summer slowdown in member engagement, characterizing the seasonal weakness as temporary but enough to spook markets.
- Full-year revenue guidance was modestly trimmed to $1.36 billion–$1.385 billion at the midpoint, while adjusted EPS guidance was raised to $2.04–$2.10.
- Broader healthcare and mid-cap growth sectors showed mixed performance Friday, but PGNY's move was overwhelmingly earnings-driven rather than a sector-wide phenomenon.
- Traders are now watching for stabilization around key technical levels and the company's next selling-season update for signs of reaccelerating growth.
Opening Summary
Shares of PGNY, the fertility and family-building benefits management company Progyny, Inc., plunged 8.61% to $27.61 during Friday's trading session, extending losses that began in after-hours trading Thursday evening. The stock closed the prior session at $30.21 and had already shed roughly 3.7% during Thursday's regular trading. The selloff was triggered by the company's second-quarter fiscal 2026 earnings results, released after the bell on August 6, where stronger-than-expected Q2 figures were overshadowed by third-quarter revenue guidance that fell materially short of analyst expectations.
Q2 Earnings: A Beat That Wasn't Enough
At first glance, Progyny's second-quarter numbers appeared solid. Revenue rose 5.3% year-over-year to $350.5 million, narrowly exceeding consensus estimates of roughly $348.5 million. Adjusted earnings per share came in at $0.55, comfortably above the analyst consensus of around $0.34 to $0.52 depending on the estimate set. Adjusted EBITDA reached $62.1 million, yielding a 17.7% margin, and gross margin expanded 180 basis points year-over-year to 25.5%, driven by efficiencies in care management and service delivery.
CEO Pete Anevski noted that member engagement trended toward the higher end of expectations during the quarter, with members continuing to pursue family-building and health and well-being services. The company also highlighted strong selling-season momentum, with early client commitments pacing meaningfully ahead of the prior year. On the capital-allocation front, Progyny repurchased nearly 1.2 million shares for $31.5 million during the quarter under its $200 million buyback program, reducing shares outstanding by approximately 12.5% since November.
Guidance Disappointment: Summer Slowdown Weighs on Q3 Outlook
The problem for investors was not the rearview mirror but the road ahead. Progyny issued third-quarter revenue guidance of $335 million to $345 million, a range whose midpoint of $340 million landed roughly 3% below the analyst consensus of approximately $350.6 million. Q3 adjusted EBITDA guidance of $56 million to $59 million and adjusted EPS guidance of $0.50 to $0.52 also came in at or below Street expectations.
Management explained on the earnings call that the company is experiencing a more pronounced summer seasonality effect, where member engagement softens during peak vacation months. CFO Mark Livingston characterized the adjustment as modest—roughly a 1% change at the midpoint—and emphasized that the company has visibility into September as appointment scheduling builds. However, the market seized on the near-term growth deceleration, punishing the stock despite management's insistence that the pattern is temporary rather than structural.
Full-Year Guidance Trimmed
For the full fiscal year 2026, Progyny narrowed its revenue outlook to $1.36 billion to $1.385 billion, representing growth of 5.5% to 7.5%. While the adjusted EPS guidance range was raised to $2.04–$2.10 from a prior range of $1.98–$2.09, the revenue midpoint came down modestly from prior guidance. Adjusted EBITDA was also narrowed to $233 million to $240 million. The slight downward revision, combined with the Q3 miss, fueled concerns that growth momentum may be decelerating faster than anticipated, particularly as the company laps the contribution from a large former client whose transition-of-care agreement ended in mid-2025.
Market Context and Trading Activity
Trading volume in PGNY was significantly elevated during Thursday's after-hours session and continued heavy into Friday, well above the stock's average daily volume of approximately 1.5 million shares. The decline far outpaced any broader healthcare-sector moves, confirming the move was company-specific. PGNY had rallied more than 27% over the prior three months, driven by optimism around the selling season and accelerating earnings, making the stock particularly vulnerable to any guidance disappointment. The selloff pushed shares below the 50-day moving average, a technical level that had previously provided support during the stock's spring and summer advance.
What Comes Next for PGNY
Looking ahead, Progyny's fundamental story remains anchored in several durable tailwinds: an expanding client base that reached 604 total clients by quarter-end, growing covered lives, and a new fully insured product offering called Progyny Select that could open additional market segments over time. The company's balance sheet remains strong, with $237 million in cash and marketable securities and no debt, providing ample flexibility for continued share repurchases and strategic investments.
However, risks remain. The competitive environment in fertility benefits is intensifying, and the company must demonstrate that the summer seasonal softness is indeed temporary when third-quarter results arrive. The upcoming 2027 selling season will be a critical catalyst—early commitments are reportedly pacing ahead of last year, which could rebuild confidence if those commitments convert into realized revenue growth. Analysts remain broadly constructive, with a consensus Moderate Buy rating and a median price target well above current levels, but the near-term narrative will be dictated by whether Q3 engagement rebounds as management expects.
Trending AI Robots
For traders seeking data-driven strategies amid volatile earnings-season moves like Progyny's, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots actively navigating current market conditions. Tickeron provides hundreds of algorithmic trading bots spanning thousands of tickers and strategies, but only the strongest performers—ranked by real-time metrics—are featured in the Trending AI Robots section. Bots vary by trading style, holding period, risk profile, and the symbols they trade, allowing users to explore approaches aligned with their own objectives. Visit the Trending AI Robots page to discover which strategies are leading in today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
PGNY's RSI Oscillator slumps oversold zone
The RSI Indicator for PGNY moved into overbought territory on August 07, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where PGNY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PGNY advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .
PGNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 209 cases where PGNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGNY as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PGNY turned negative on July 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
PGNY moved below its 50-day moving average on August 07, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PGNY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.864) is normal, around the industry mean (3.838). P/E Ratio (30.587) is within average values for comparable stocks, (148.594). PGNY's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.262). PGNY's Dividend Yield (0.000) is considerably lower than the industry average of (0.020). PGNY's P/S Ratio (1.864) is very high in comparison to the industry average of (0.598).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools
Industry ManagedHealthCare
Advertisement